Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2952W HIGH $76.36
Volume
1.09 M
Value Traded
191.17 K
Short % Float
1.26%
+1.27%Week
+1,401.57%1 Month
+112.89%3 Month
-64.91%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.49 M
EPS (TTM)
-70.72
P/E Ratio
-
Ent. Value
-1.30 M
Total Shares
520.09 K
Float Shares
1.72 M
Insiders
11.52%
Institutions
0.02%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
JAGX Catalyst Timeline
Dated clinical, regulatory and corporate events for Jaguar Health, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Jaguar Health, Inc.
434Total events
15Upcoming
98Tier-1 (high impact)
2015 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Quarterly UpdateCorporate
Board declared special stock dividend of Series R Convertible Preferred Stock
▲AbstractCrofelemerApprovedPresentation
Abstract on preliminary results of open-label crofelemer study in adult SBS-IF accepted for ACG 2026 presentation
short bowel syndrome with intestinal failure (SBS-IF)source ↗
▲Other Regulator MilestoneCrofelemerApprovedEx-US Regulatory
FDA granted PDUFA fee waiver for Mytesi for FY2027
▲Other Regulator MilestoneCanalevia-CA1ApprovedEx-US Regulatory
FDA Center for Veterinary Medicine granted fee waiver for Canalevia-CA1 for FY2027
chemotherapy-induced diarrhea in dogssource ↗
●Timing GuidancePresentation
Jaguar Health common stock to begin trading on split-adjusted basis
●Quarterly UpdateCorporate
Jaguar Health common stock begins trading on split-adjusted basis on Nasdaq
▲Enrollment CompleteCrofelemerApprovedTrial
All randomized pediatric MVID patients entered single-blind extension phase of pivotal crofelemer trial
Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)source ↗
▲Product LaunchPost-Market
Neonorm Dog now available on Amazon
support of normal stool consistency and GI fluid balance in dogssource ↗
▲Trial CompletionCrofelemerApprovedTrial
Completed randomized double-blind treatment phase in pivotal MVID trial
microvillus inclusion diseasesource ↗
▲Primary CompletionCrofelemerApprovedTrial
Completed randomized double-blind treatment phase in pivotal trial in pediatric MVID patients
microvillus inclusion diseasesource ↗
▲Oral PresentationCrofelemerApprovedPresentation
Data from ongoing investigational studies with oral liquid crofelemer in pediatric IF patients presented at 58th ESPGHAN Meeting
intestinal failure due to MVID and SBS-IF (pediatric)source ↗
▲Additional DataCrofelemerApprovedClinical Data
Data presented at 58th ESPGHAN Meeting from ongoing pediatric IF studies of oral liquid crofelemer
intestinal failure due to MVID and SBS-IFsource ↗
●Oral PresentationPresentation
Jaguar CEO Lisa Conte to present at Lytham Partners Spring 2026 Investor Conference
●Quarterly UpdateCorporate
Jaguar to host investor webcast on Q1 2026 financials and company updates
◆Restructuring LayoffsCorporate
Nasdaq extension granted until May 15, 2026 to demonstrate compliance with bid price rule
◆Breakthrough Therapy DesignationCrofelemerApprovedDesignation
Plan to seek Breakthrough Therapy designation from FDA for crofelemer in MVID
microvillus inclusion disease (MVID)source ↗
◆Partnership / LicenseCrofelemerApprovedCorporate
Business development discussions for non-dilutive funding from potential partners
intestinal failure (IF) indicationssource ↗
▲Milestone PaymentCorporate
Received $3.0M of up to $20M in milestone payments from Future Pak
◆Management ChangeCorporate
Appeal of Nasdaq noncompliance determination at hearing on April 7, 2026
●Corporate ApprovalCorporate
Stockholders approve reverse stock split proposal at April 2026 Special Meeting
◆Breakthrough Therapy DesignationCrofelemerApprovedDesignation
Hope to achieve Breakthrough Therapy designation for crofelemer in MVID
microvillus inclusion disease (MVID)source ↗
◆Topline ReadoutCrofelemerApprovedClinical Data
Study results expected for crofelemer in MVID and SBS-IF
microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF)source ↗
◆Trial CompletionCanalevia-CA1ApprovedTrial
Confirmatory effectiveness trial for Canalevia-CA1 expected to conclude in February 2026
chemotherapy-induced diarrhea (CID) in dogssource ↗
◆Debt Royalty FinancingCorporate
Extension of maturity date of convertible promissory notes from bridge financing to January 30, 2026
▲Partnership / LicenseCrofelemerApprovedCorporate
U.S. license agreement with Future Pak for crofelemer (Mytesi and Canalevia-CA1)
▲Partnership / LicenseCrofelemerApprovedCorporate
Jaguar enters U.S. licensing agreement with Woodward/Future Pak for Mytesi and Canalevia-CA1
noninfectious diarrhea in HIV/AIDSsource ↗
▲Partnership / LicenseCanalevia-CA1ApprovedCorporate
Jaguar enters U.S. licensing agreement with Woodward/Future Pak for Mytesi and Canalevia-CA1
chemotherapy-induced diarrhea in dogssource ↗
▲FDA Feedback ReceivedCanalevia-CA1ApprovedFDA Meeting
FDA CVM awarded $240,000 grant for Canalevia-CA1 CID study
chemotherapy-induced diarrhea (CID) in dogssource ↗
▲Partnership / LicenseCrofelemerApprovedCorporate
U.S. license agreement with Future Pak for Mytesi and Canalevia-CA1
noninfectious diarrhea in HIV/AIDSsource ↗
▲Partnership / LicenseCanalevia-CA1ApprovedCorporate
U.S. license agreement with Future Pak for Mytesi and Canalevia-CA1
chemotherapy-induced diarrhea in dogssource ↗
▲FDA ApprovalCanalevia-CA1ApprovedFDA Decision
FDA renewed conditional approval for Canalevia-CA1 for fifth and final year through December 21, 2026
chemotherapy-induced diarrhea (CID) in dogssource ↗
◆Oral PresentationPresentation
Jaguar CEO Lisa Conte presenting at Emerging Growth Conference
▲Topline ReadoutCrofelemerApprovedClinical Data
Initial results of investigator-initiated proof-of-concept trial in MVID
microvillus inclusion disease (MVID)source ↗
◆FDA Feedback ReceivedCrofelemerApprovedFDA Meeting
FDA meeting completed for advice on advancing placebo-controlled trial for MVID
microvillus inclusion disease (MVID)source ↗
▲Topline ReadoutCrofelemerApprovedClinical Data
Initial proof-of-concept results: crofelemer reduced TPN in first MVID patient by up to 27%
microvillus inclusion disease (MVID)source ↗
▲FDA Feedback ReceivedCrofelemerApprovedFDA Meeting
FDA meeting resulted in planned regulatory pathway to complete supplemental NDA strategy for crofelemer in metastatic breast cancer
metastatic breast cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How JAGX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-10-31 | crofelemer | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$1M
Pipeline Value
$28M
Commercial Value
Undervalued
Valuation Signal
1
Drugs Scored
0.7x
rNPV / MCap
Top 71%
Micro Cap(rank 469 of 660)
Percentile Rank
Jaguar Health, Inc. faces pipeline headwinds (29/100), with $173M risk-adjusted pipeline value, led by Crofelemer in Microvillus Inclusion Disease (Phase 2), but cash runway is a concern.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $27.8M x 1.0 = $28M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Mytesi | $8M | $11M | -27.4% |
| Canalevia | $0M | $0M | +99.4% |
| Gelclair | $0M | - | - |
| Neonorm | $0M | $0M | -45.7% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Crofelemer Small moleculeMarketedNCT04538625 | Cancer Therapy-Related Diarrhea | Phase 3 | COMPLETED | 287 | Oct 30, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every JAGX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| crofelemer | microvillus inclusion disease (MVID) and short bowel syndrome (SBS) | 2026-10-06 | substantial reductions in weekly PS needs; PS normalized to body weight in pediatric IF patients dosed orally for more than one year; no significant clinical or laboratory abnormalitiesRead More | Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu DhabiRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MICEK JOHNDirector | Grant/Award | 7,377 7,377 held | $0.00 | 12/11/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in JAGX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in JAGX for Q2 2026. | ||||
JAGX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How JAGX ranks across every disease it competes in
Competitive Position is a premium feature
See how JAGX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialJAGX News
-JAGX
Oct 6, 2026▲ +18.8%on this news
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Napo Pharmaceuticals, part of Jaguar Health, is sponsoring a panel discussion at the 2nd Best of Elite Ped-GI meeting in Abu Dhabi. The focus is on the development of crofelemer for treating microvillus inclusion disease (MVID) and short bowel syndrome (SBS). The company aims to file a New Drug Application for MVID by mid-2027, supported by promising clinical data.
Read more →-JAGX
Oct 2, 2026▲ +29.2%on this news· ran to +54% by day 1shared move
Jaguar Health Announces a Special Stock Dividend
Jaguar Health has declared a special stock dividend to its shareholders, consisting of Series R Convertible Preferred Stock. This move aims to reward stockholders and protect against dilution as the company evaluates strategic alternatives. The Preferred Stock will convert into Common Stock on November 2, 2026. Jaguar continues to focus on its intestinal failure program and plans to file a New Drug Application for crofelemer in mid-2027.
Read more →-JAGX
Sep 29, 2026▼ -11.6%on this news· ran to -39% by day 3
Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
Jaguar Health, Inc. announced that preliminary results from an open-label study of crofelemer for adult patients with short bowel syndrome with intestinal failure have been accepted for presentation at the ACG 2026 meeting. The company is also conducting a Phase 2 clinical trial, with results anticipated in 2027. Crofelemer aims to serve as an adjunctive therapy to parenteral support for rare gastrointestinal disorders.
Read more →-JAGX
Sep 22, 2026▲ +1190.6%on this news
Jaguar Health Receives Fee Waivers from FDA
Jaguar Health, Inc. announced that the FDA has granted fee waivers for its drugs Mytesi and Canalevia for the 2027 fiscal year. Mytesi is approved for treating noninfectious diarrhea in HIV/AIDS patients, while Canalevia is conditionally approved for chemotherapy-induced diarrhea in dogs. The company aims to file a New Drug Application for crofelemer targeting microvillus inclusion disease by mid-2027.
Read more →-JAGX
Sep 15, 2026▼ -29.6%on this news· ran to -43% by day 3
Jaguar Health, Inc. Announces Reverse Stock Split
Jaguar Health, Inc. has announced a reverse stock split of its common stock at a 1-for-15 ratio, effective September 17, 2026. This decision follows approval from stockholders during the April 2026 Special Meeting. The split aims to help the company meet Nasdaq's listing standards, with shares trading on a split-adjusted basis thereafter.
Read more →-JAGX
Sep 10, 2026▼ -12.9%on this news· ran to -39% by day 3
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Jaguar Health announced that all randomized pediatric patients in its pivotal trial for crofelemer have entered a single-blind extension phase. This phase aims to assess the long-term safety and efficacy of crofelemer as an adjunct therapy for microvillus inclusion disease (MVID). The trial's results are expected to support a New Drug Application (NDA) filing by mid-2027.
Read more →-JAGX
Sep 8, 2026▼ -30.6%on this news· ran to -47% by day 3shared move
Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Jaguar Health has launched Neonorm Dog, a non-prescription, plant-based product aimed at supporting normal stool consistency and GI fluid balance in dogs. Available on Amazon, this product expands the Neonorm franchise, which previously included options for foals and calves. The company anticipates further availability through other retail channels, such as Chewy.
Read more →-JAGX
Sep 4, 2026▼ -14.1%on this news· ran to -54% by day 3shared move
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Jaguar Health announced the compassionate use of crofelemer for an infant patient with intestinal failure due to congenital sodium diarrhea. The company is focused on developing crofelemer as an adjunctive therapy for rare pediatric conditions, including microvillus inclusion disease. Positive data from ongoing studies support the potential of crofelemer to reduce parenteral support needs in affected patients. An NDA filing for crofelemer for microvillus inclusion disease is planned for mid-2027.
Read more →-JAGX
Aug 26, 2026Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Jaguar Health has launched Neonorm Dog, a non-prescription plant-based product aimed at supporting normal stool consistency and gastrointestinal fluid balance in dogs. This product extends the existing Neonorm franchise, which previously catered to foals and calves. Neonorm Dog will be available through major online platforms, enhancing Jaguar's presence in the companion animal market.
Read more →-JAGX
Aug 19, 2026▼ -5.5%on this news
Jaguar Health Reports Second Quarter 2026 Financials
Jaguar Health reported its second-quarter 2026 financial results, highlighting ongoing development of crofelemer for rare intestinal failure diseases. The company announced promising results from a presentation at ESPGHAN 2026, showing a significant reduction in parenteral support for pediatric patients. However, the company faced challenges, including a net loss increase and a notable drop in prescription product revenue compared to the previous year.
Read more →-JAGX
Aug 18, 2026▲ +11.1%on this newsshared move
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates
Jaguar Health, Inc. announced an investor webcast scheduled for August 19, 2026, to discuss its Q2 2026 financials and corporate updates. The company plans to file its Earnings Report on Form 10-Q for the quarter ending June 30, 2026. This initiative reflects the company's commitment to keeping investors informed.
Read more →-JAGX
Jun 10, 2026Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
Jaguar Health, Inc. announced the approval of all five proposals at its Annual Meeting of Stockholders held on June 8, 2026. The proposals were previously outlined in the definitive proxy statement filed with the SEC. Additionally, Jaguar's founder, Lisa Conte, is scheduled to present at the Emerging Growth Conference on June 10, 2026. The company specializes in developing plant-derived prescription drugs for gastrointestinal disorders.
Read more →-JAGX
May 27, 2026Jaguar Health Compliant with Nasdaq Bid Price Rule JAGX's securities continue to be listed and traded on Nasdaq
Jaguar Health, Inc. announced that it has regained compliance with Nasdaq's listing rule, allowing its securities to remain traded on the exchange. This comes after reporting an impressive 816% increase in net revenue in Q1 2026 compared to the same period in the previous year. The company is focusing on its development program for an innovative oral formulation of crofelemer, aiming for a new drug application by mid-2027. Jaguar is also looking for a commercialization partner for this project.
Read more →-JAGX
May 21, 2026▼ -5.4%on this news· ran to -21% by day 1shared move
Jaguar Health Reports First Quarter 2026 Financials
Jaguar Health reported a remarkable 816% increase in net revenue for Q1 2026 compared to Q1 2025, driven by a licensing agreement for Mytesi and Canalevia-CA1. The company is focusing on developing crofelemer for rare intestinal failure diseases, with presentations planned at the upcoming ESPGHAN meeting. Despite the positive revenue growth, prescription product revenue saw a significant decline from the previous quarter.
Read more →-JAGX
Apr 27, 2026▼ -27.8%on this news· ran to -49% by day 3
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split
Jaguar Health, Inc. has been granted an extension until May 15, 2026, to demonstrate compliance with Nasdaq's $1.00 bid price rule, following a formal notice from the Nasdaq Hearings Panel. To aid this process, the company will execute a reverse stock split at a 1-for-35 ratio, effective April 30, 2026. This split aims to increase the per-share price of its stock and maintain its listing on the Nasdaq Capital Market. The decision to split shares was approved during a Special Meeting of Stockholders.
Read more →-JAGX
Apr 21, 2026Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
Jaguar Health, Inc. announced the successful approval of five proposals at its Special Meeting of Stockholders held on April 20, 2026. The details of these proposals can be found in the definitive proxy statement filed with the SEC. This approval indicates strong support from shareholders for the company's strategic direction.
Read more →-JAGX
Apr 14, 2026Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health’s Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
Jaguar Health plans to leverage AI platforms to enhance the development and commercialization of crofelemer for intestinal failure, particularly in pediatric patients with microvillus inclusion disease (MVID). The company aims to demonstrate crofelemer's effectiveness and achieve faster FDA approval, addressing a critical unmet medical need. Progress includes a notable reduction in parenteral support in treatment programs and discussions for non-dilutive funding.
Read more →-JAGX
Apr 7, 2026Jaguar Health Reports 2025 Financials
Jaguar Health reported a 5% increase in net revenue for the fourth quarter of 2025 compared to the previous quarter, aided by a $16 million upfront payment from Future Pak for product licensing. The company is shifting its focus towards developing its crofelemer products for rare disease indications. However, it continues to face significant operational losses and challenges related to Nasdaq compliance, which may affect its listing status. An investor webcast has been scheduled for April 10, 2026, to discuss these results and future plans.
Read more →-JAGX
Feb 18, 2026Jaguar Health Announces a Special One-time Stock Dividend
Jaguar Health, Inc. has declared a one-time special stock dividend to its shareholders, consisting of Series O Convertible Preferred Stock. This initiative aims to protect against dilution while the company explores debt restructuring. The Preferred Stock will convert into Common Stock at the Board's discretion, with a planned NDA filing for a rare disease treatment in 2027.
Read more →-JAGX
Jan 12, 2026▼ -21%on this news· ran to -34% by day 1
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
Jaguar Health has entered into a U.S. licensing agreement with Future Pak, allowing Future Pak to exclusively market Mytesi and Canalevia-CA1. The agreement includes an $18 million upfront payment, with potential future milestone payments totaling up to $20 million. This partnership aims to enhance the market presence of Jaguar’s products while providing them with non-dilutive capital to support their rare-disease pipeline. Jaguar continues to manage the manufacturing of Mytesi and Canalevia-CA1, retaining strategic control over its products.
Read more →About Jaguar Health, Inc.
Headquarters200 PINE STREET SUITE 400, SAN FRANCISCO, CA, 94104
BIOPHARMAWATCH ELITE PLUS
Trade the next JAGX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime